172 related articles for article (PubMed ID: 9553099)
1. Residues 21-30 within the extracellular N-terminal region of the C5a receptor represent a binding domain for the C5a anaphylatoxin.
Chen Z; Zhang X; Gonnella NC; Pellas TC; Boyar WC; Ni F
J Biol Chem; 1998 Apr; 273(17):10411-9. PubMed ID: 9553099
[TBL] [Abstract][Full Text] [Related]
2. Site-directed mutagenesis of conserved charged residues in the helical region of the human C5a receptor. Arg2O6 determines high-affinity binding sites of C5a receptor.
Raffetseder U; Röper D; Mery L; Gietz C; Klos A; Grötzinger J; Wollmer A; Boulay F; Köhl J; Bautsch W
Eur J Biochem; 1996 Jan; 235(1-2):82-90. PubMed ID: 8631370
[TBL] [Abstract][Full Text] [Related]
3. Stabilization of an isolated helical capping box in solution by hydrophobic interactions: evidence from the NMR study of bioactive peptides from the C-terminus of human C5a anaphylatoxin.
Ni F; Carpenter KA; Ripoll DR; Sanderson SD; Hugli TE
Biopolymers; 1996 Jan; 38(1):31-41. PubMed ID: 8679942
[TBL] [Abstract][Full Text] [Related]
4. Chimeric receptors of the human C3a receptor and C5a receptor (CD88).
Crass T; Ames RS; Sarau HM; Tornetta MA; Foley JJ; Köhl J; Klos A; Bautsch W
J Biol Chem; 1999 Mar; 274(13):8367-70. PubMed ID: 10085065
[TBL] [Abstract][Full Text] [Related]
5. Site-specific mutagenesis of residues in the human C5a anaphylatoxin which are involved in possible interaction with the C5a receptor.
Bubeck P; Grötzinger J; Winkler M; Köhl J; Wollmer A; Klos A; Bautsch W
Eur J Biochem; 1994 Feb; 219(3):897-904. PubMed ID: 8112341
[TBL] [Abstract][Full Text] [Related]
6. Human complement 5a (C5a) anaphylatoxin receptor (CD88) phosphorylation sites and their specific role in receptor phosphorylation and attenuation of G protein-mediated responses. Desensitization of C5a receptor controls superoxide production but not receptor sequestration in HL-60 cells.
Christophe T; Rabiet MJ; Tardif M; Milcent MD; Boulay F
J Biol Chem; 2000 Jan; 275(3):1656-64. PubMed ID: 10636859
[TBL] [Abstract][Full Text] [Related]
7. Solution structure of a unique C5a semi-synthetic antagonist: implications in receptor binding.
Zhang X; Boyar W; Galakatos N; Gonnella NC
Protein Sci; 1997 Jan; 6(1):65-72. PubMed ID: 9007977
[TBL] [Abstract][Full Text] [Related]
8. Mapping the ligand-binding site on the C5a receptor: arginine74 of C5a contacts aspartate282 of the C5a receptor.
Cain SA; Coughlan T; Monk PN
Biochemistry; 2001 Nov; 40(46):14047-52. PubMed ID: 11705397
[TBL] [Abstract][Full Text] [Related]
9. C5a receptor antagonists.
Pellas TC; Wennogle LP
Curr Pharm Des; 1999 Oct; 5(10):737-55. PubMed ID: 10526086
[TBL] [Abstract][Full Text] [Related]
10. Mutation of glutamate 199 of the human C5a receptor defines a binding site for ligand distinct from the receptor N terminus.
Monk PN; Barker MD; Partridge LJ; Pease JE
J Biol Chem; 1995 Jul; 270(28):16625-9. PubMed ID: 7622471
[TBL] [Abstract][Full Text] [Related]
11. Direct binding of a fragment of the Wiskott-Aldrich syndrome protein to the C-terminal end of the anaphylatoxin C5a receptor.
Tardif M; Brouchon L; Rabiet MJ; Boulay F
Biochem J; 2003 Jun; 372(Pt 2):453-63. PubMed ID: 12600272
[TBL] [Abstract][Full Text] [Related]
12. Small molecular probes for G-protein-coupled C5a receptors: conformationally constrained antagonists derived from the C terminus of the human plasma protein C5a.
Wong AK; Finch AM; Pierens GK; Craik DJ; Taylor SM; Fairlie DP
J Med Chem; 1998 Aug; 41(18):3417-25. PubMed ID: 9719594
[TBL] [Abstract][Full Text] [Related]
13. Genetic mapping of the human C5a receptor. Identification of transmembrane amino acids critical for receptor function.
Geva A; Lassere TB; Lichtarge O; Pollitt SK; Baranski TJ
J Biol Chem; 2000 Nov; 275(45):35393-401. PubMed ID: 10952985
[TBL] [Abstract][Full Text] [Related]
14. Evidence that the extracellular N-terminal domain of C5aR contains amino-acid residues crucial for C5a binding.
Mery L; Boulay F
Eur J Haematol; 1993 Nov; 51(5):282-7. PubMed ID: 8282089
[TBL] [Abstract][Full Text] [Related]
15. Identification of the major phosphorylation sites in human C5a anaphylatoxin receptor in vivo.
Giannini E; Brouchon L; Boulay F
J Biol Chem; 1995 Aug; 270(32):19166-72. PubMed ID: 7642584
[TBL] [Abstract][Full Text] [Related]
16. Modulation of ligand selectivity by mutation of the first extracellular loop of the human C5a receptor.
Cain SA; Woodruff TM; Taylor SM; Fairlie DP; Sanderson SD; Monk PN
Biochem Pharmacol; 2001 Jun; 61(12):1571-9. PubMed ID: 11377387
[TBL] [Abstract][Full Text] [Related]
17. Biologically active conformer of the effector region of human C5a and modulatory effects of N-terminal receptor binding determinants on activity.
Finch AM; Vogen SM; Sherman SA; Kirnarsky L; Taylor SM; Sanderson SD
J Med Chem; 1997 Mar; 40(6):877-84. PubMed ID: 9083476
[TBL] [Abstract][Full Text] [Related]
18. The NH2-terminal region of C5aR but not that of FPR is critical for both protein transport and ligand binding.
Mery L; Boulay F
J Biol Chem; 1994 Feb; 269(5):3457-63. PubMed ID: 8106386
[TBL] [Abstract][Full Text] [Related]
19. C5a receptor activation. Genetic identification of critical residues in four transmembrane helices.
Baranski TJ; Herzmark P; Lichtarge O; Gerber BO; Trueheart J; Meng EC; Iiri T; Sheikh SP; Bourne HR
J Biol Chem; 1999 May; 274(22):15757-65. PubMed ID: 10336477
[TBL] [Abstract][Full Text] [Related]
20. Sulfated tyrosines contribute to the formation of the C5a docking site of the human C5a anaphylatoxin receptor.
Farzan M; Schnitzler CE; Vasilieva N; Leung D; Kuhn J; Gerard C; Gerard NP; Choe H
J Exp Med; 2001 May; 193(9):1059-66. PubMed ID: 11342590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
